viewFSD Pharma

Nasdaq newbie FSD Pharma to ring opening bell next Wednesday

The Toronto-based pharmaceutical cannabis company started trading on the US exchange last week

Nasdaq building
FSD is the first company trading on the CSE to ever achieve a Nasdaq listing

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE), a pharmaceutical cannabis research company, will ring the Nasdaq opening bell on Wednesday, January 22. 

The Toronto-based company began trading on the US exchange on January 9. The newly-christened firm will be represented by CEO Raza Bokhari, along with members of the board, leadership team, early investors and others. 

“It will indeed be a unique privilege for me to ring the opening bell at Nasdaq to commence trading in the presence of FSD Pharma’s extended family and friends," Bokhari said in a statement. "The recent listing of our Class B Subordinate Voting Shares on Nasdaq has included us in a select group of 12 Canadian-domiciled cannabis companies that trade on a major U.S. exchange.”

In fact, FSD is the first company trading on the Candian Securities Exchange to ever achieve a Nasdaq listing, according to a tweet from the exchange last week.

Bokhari, for his part, is ready to separate FSD from the pack.

“I am, however, very hopeful that sooner rather than later we will be placed in a league of our own as we continue to demonstrate that the primary thrust of our business is to focus on conducting clinical trials on synthetic compounds with anti-inflammatory properties that target the CB2 receptor of the endocannabinoid system of the human body," he added.

The bell-ringing ceremony will be webcast on the Nasdaq’s website and livestreamed on Facebook beginning at 9:20 am ET.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com 

Follow him on Twitter @andrew_kessel

Quick facts: FSD Pharma

Price: 3.64 CAD

Market: CSE
Market Cap: $53.59 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...


FSD Pharma aims to initiate a Phase 2 coronavirus treatment trial by end...

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE.CN) (FRA:0K9A) CEO Raza Bokhari tells Proactive the group has submitted an Investigational New Drug (IND) application to the FDA for the use of its lead candidate FSD-201, or anti-inflammatory ultra-micronized-palmitoylethanolamide (PEA), to treat...

1 week, 3 days ago

2 min read